Reaction

Maternal Exposure During Breast Feeding reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,869 reports · 88 co-occurring drugs

As of the last recalculation, Maternal Exposure During Breast Feeding appears in 3,869 FAERS reports alongside 88 co-occurring drug terms. The strongest observed disproportionality signal is CERTOLIZUMAB PEGOL (PRR 45.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Certolizumab Pegol	791	45.4	45.7
Vedolizumab	239	15.8	15.9
Brivaracetam	26	15.7	15.7
Docusate Sodium 100Mg	61	13.9	14.0
Lamotirigine	177	13.9	13.9
Lamotrigine Extended-Release	177	13.9	13.9
Lamotrigine Chewable Dispersible	177	13.9	13.9
Ursosiol	45	12.6	12.6
Lacosamide	81	11.9	12.0
Ursodiol	45	11.2	11.3
Mesalamine	106	10.4	10.4
Methylphenidate	54	10.2	10.2
Levetiracetam In Sodium Chloride	135	9.7	9.7
Levetiracetam Oral	135	9.7	9.7
Levetiracetam Injection	135	9.7	9.7
Labetalol	21	8.5	8.5
Lamotrigine	199	8.5	8.5
Aripiprazole Oral	64	8.4	8.5
Aripiprazole Orally Disintegrating	64	8.4	8.5
Methylphenidate Hydrochloride	78	7.2	7.2
Etonogestrel	63	7.2	7.2
Cyclobenzaprine	65	7.1	7.1
Nicotine Polacrilex Mini	19	6.8	6.8
Nicotine Polarilex	19	6.8	6.8
Sumatriptan Succinate	31	6.6	6.7
Levetiracetam	158	6.6	6.6
Ferrous Sulfate	60	6.5	6.5
Methadone Hydrochloride	13	6.5	6.5
Duloxetine	81	6.4	6.4
Iron	75	6.1	6.1
Docusate Sodium	63	6.0	6.0
Sertraline	126	5.9	5.9
Azathioprine	95	5.9	5.9
Agalsidase Beta	10	5.8	5.8
Tranexamic Acid	9	5.5	5.5
Cetiirizine	42	5.4	5.4
Isoniazid	15	5.0	5.0
Buspirone Hydrochloride	10	4.9	4.9
Ofatumumab	28	4.6	4.6
Glatiramer Acetate	50	4.5	4.6
Cetirizine	63	4.4	4.4
Sumatriptan	31	4.4	4.4
Liothyronine Sodium	7	4.3	4.3
Progesterone	18	4.2	4.3
Cetirizine Hydrochloride Allergy	23	4.1	4.1
Cetirizine Hydrochloride Tablets	23	4.1	4.1
Colchicine	20	4.1	4.1
Phenobarbital	11	4.1	4.1
Insulin	42	4.1	4.1
Calcitriol Capsules 0.25 Mcg	15	4.0	4.0
Calcitriol Capsules 0.5 Mcg	15	4.0	4.0
Calcitriol	15	4.0	4.0
Metronidazole Topical	35	4.0	4.0
Hydroxychloroquine	53	3.9	3.9
Clobetasol Propionate Ointment Usp, 0.05%	7	3.7	3.7
Clobetasol Propionate	7	3.6	3.6
Buprenorphine Hydrochloride, Naloxone Hydrochloride	16	3.6	3.6
Eculizumab	34	3.4	3.4
Insulin Human	24	3.3	3.3
Amphetamine	5	3.3	3.3
Aripiprazole	72	3.2	3.2
Miconazole Nitrate	5	3.1	3.1
Clobazam	13	2.9	2.9
Rocuronium Bromide	6	2.7	2.7
Nicotine Polacrilex	19	2.7	2.7
Pegvaliase-Pqpz	4	2.6	2.6
Rimegepant Sulfate	6	2.5	2.6
Nicotine	19	2.5	2.5
Ocrelizumab	29	2.5	2.5
Peginterferon Beta-1A	6	2.5	2.5
Onabotulinumtoxina	34	2.4	2.4
Insulin Lispro	60	2.4	2.4
Galcanezumab-Gnlm	13	2.2	2.2
Levonorgestrel	79	2.1	2.1
Lurasidone Hydrochloride	8	2.1	2.1
Brexpiprazole	6	1.9	1.9
Guselkumab	12	1.8	1.8
Cenegermin-Bkbj	4	1.8	1.8
Cariprazine	3	1.7	1.7
Crisaborole	3	1.7	1.7
Ravulizumab	4	1.6	1.6
Bimekizumab	6	1.5	1.5
Fremanezumab-Vfrm	3	1.4	1.4
Dupilumab	117	1.3	1.3
Ixekizumab	8	1.2	1.2
Tirzepatide	34	1.1	1.1
Copper	4	0.5	0.5
Adapalene	11	0.3	0.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.